AXT 2001
Alternative Names: AXT-2001Latest Information Update: 28 Aug 2023
At a glance
- Originator Axter Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer; Prostate cancer; Sarcoma; Skin cancer
Most Recent Events
- 10 Aug 2023 Preclinical trials in Ovarian cancer in China (unspecified route), prior to August (Axter Therapeutics pipeline, August 2023)
- 10 Aug 2023 Preclinical trials in Prostate cancer in China (unspecified route), prior to August (Axter Therapeutics pipeline, August 2023)
- 10 Aug 2023 Preclinical trials in Sarcoma in China (unspecified route), prior to August (Axter Therapeutics pipeline, August 2023)